Chemistry:Voxtalisib
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H14N6O |
| Molar mass | 270.296 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Voxtalisib (XL-765, SAR245409) is a drug which acts as a dual inhibitor of the kinase enzymes phosphatidylinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). It is in clinical trials for the treatment of various types of cancer.[1][2][3][4][5]
References
- ↑ "Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide". Neuro-Oncology 13 (4): 384–92. April 2011. doi:10.1093/neuonc/noq193. PMID 21317208.
- ↑ "Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models". Tumour Biology 37 (1): 341–51. January 2016. doi:10.1007/s13277-015-3725-3. PMID 26219891.
- ↑ "Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial". The Lancet. Haematology 5 (4): e170–e180. April 2018. doi:10.1016/S2352-3026(18)30030-9. PMID 29550382.
- ↑ "Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches". PLOS ONE 14 (6): e0219180. 2019. doi:10.1371/journal.pone.0219180. PMID 31247018. Bibcode: 2019PLoSO..1419180R.
- ↑ "Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?". International Journal of Molecular Sciences 21 (3): 1060. February 2020. doi:10.3390/ijms21031060. PMID 32033478.
 |  |
